Abstract

The burden of cancer-related pulmonary embolism (PE) on patients and healthcare systems is substantial. Patients with acute PE from 2002 to 2014 underwent a retrospective cross-sectional examination of the National Inpatient Sample (NIS) database. We looked into the variations in clinical outcomes and healthcare use between PE patients who had cancer and those who did not. To quantify the effect of cancer on clinical outcomes, adjusted odds ratios (OR) were calculated using a multivariate logistic regression model. The differences in healthcare usage between the two groups were assessed using Wilcoxon rank sum tests. Except for coagulation deficiency, individuals with cancer showed lower prevalence of common comorbidities and a greater mean age than patients without a cancer diagnosis. A 90% increase in all-cause mortality, a longer length of stay, a higher total cost per hospitalization,and higher rates of home health services after discharge were all linked to concurrent cancer diagnosis in patients hospitalized with acute PE. The majority of cancer patients (56%) had the disease metastatic. Additionally, there were observable variations in the acute PE intervention between the two groups.